Saadettin Kilickap1, Mutlu Hayran2, Banu Cakir3, Nesrin Cilingiroglu3, Mustafa Erman2, Guldal Buyukdamgaci4, Yavuz Ozisik5. 1. Department of Medical Oncology, Cumhuriyet University Faculty of Medicine, Sivas, Ankara, Turkey. 2. Department of Preventive Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey. 3. Department of Public Health, Hacettepe University Faculty of Medicine, Ankara, Turkey. 4. Research Project Office, Bogazici University, Istanbul, Ankara, Turkey. 5. Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Abstract
BACKGROUND: The use of endocrine therapy (ET) in postmenopausal breast cancer patients may affect their cognitive status. This study aims to assess the effects of tamoxifen and aromatase inhibitors (Als) on quality of life (QoL) and cognitive functions in breast cancer patients. PATIENTS AND METHODS: The study included 101 patients receiving tamoxifen, 97 patients receiving Als, and 95 patients without any ET. All patients completed both the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the Short Form-12 (SF-12) questionnaires. RESULTS: The patients' characteristics were similar between the groups. The mean duration of ET was 2.6 years for tamoxifen and 2.5 years for Als. EORTC QLQ-C30 global scores and cognitive functioning scores as well as SF-12 mental scorings (mcs) were found not significantly different between patients without any ET and those receiving tamoxifen or Als (p = 0.529, p = 0.333, and p = 0.452, respectively). SF-12 mcs correlated moderately with EORTC QLQ-C30 global scores for the 3 treatment groups (all p values < 0.001). CONCLUSION: Our study suggests that QoL and cognitive functions are similar in patients receiving Als or tamoxifen. Moreover, it appears that these parameters also do not differ in patients with respect to the use of ET.
BACKGROUND: The use of endocrine therapy (ET) in postmenopausal breast cancerpatients may affect their cognitive status. This study aims to assess the effects of tamoxifen and aromatase inhibitors (Als) on quality of life (QoL) and cognitive functions in breast cancerpatients. PATIENTS AND METHODS: The study included 101 patients receiving tamoxifen, 97 patients receiving Als, and 95 patients without any ET. All patients completed both the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the Short Form-12 (SF-12) questionnaires. RESULTS: The patients' characteristics were similar between the groups. The mean duration of ET was 2.6 years for tamoxifen and 2.5 years for Als. EORTC QLQ-C30 global scores and cognitive functioning scores as well as SF-12 mental scorings (mcs) were found not significantly different between patients without any ET and those receiving tamoxifen or Als (p = 0.529, p = 0.333, and p = 0.452, respectively). SF-12mcs correlated moderately with EORTC QLQ-C30 global scores for the 3 treatment groups (all p values < 0.001). CONCLUSION: Our study suggests that QoL and cognitive functions are similar in patients receiving Als or tamoxifen. Moreover, it appears that these parameters also do not differ in patients with respect to the use of ET.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Cognitive function; Endocrine therapy; Quality of life; Tamoxifen
Authors: Catherine M Bender; Susan M Sereika; Adam M Brufsky; Christopher M Ryan; Victor G Vogel; Priya Rastogi; Susan M Cohen; Frances E Casillo; Sarah L Berga Journal: Menopause Date: 2007 Nov-Dec Impact factor: 2.953
Authors: Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard Journal: Breast Cancer Res Treat Date: 2010-11-03 Impact factor: 4.872
Authors: Kerstin Hermelink; Volkmar Henschel; Michael Untch; Ingo Bauerfeind; Michael Patrick Lux; Karin Munzel Journal: Cancer Date: 2008-11-01 Impact factor: 6.860
Authors: Therese B Bevers; Benjamin O Anderson; Ermelinda Bonaccio; Saundra Buys; Sandra Buys; Mary B Daly; Peter J Dempsey; William B Farrar; Irving Fleming; Judy E Garber; Randall E Harris; Alexandra S Heerdt; Mark Helvie; John G Huff; Nazanin Khakpour; Seema A Khan; Helen Krontiras; Gary Lyman; Elizabeth Rafferty; Sara Shaw; Mary Lou Smith; Theodore N Tsangaris; Cheryl Williams; Thomas Yankeelov; Thomas Yaneeklov Journal: J Natl Compr Canc Netw Date: 2009-11 Impact factor: 11.908
Authors: B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: Rebeca Stahlschmidt; Amanda Canato Ferracini; Cinthia Madeira de Souza; Luana Moreira de Medeiros; Cassia Raquel Teatin Juliato; Priscila Gava Mazzola Journal: Support Care Cancer Date: 2019-02-06 Impact factor: 3.603